Quick Answer
FibroBiologics, Inc. reported Research And Development Expense of $7.41 million for the year ending 2025.
- FibroBiologics, Inc. showed an increase of +64.5% in Research And Development Expense from 2024 to 2025.
- This data is from FibroBiologics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $478.0 thousand | Q2 2023: $547.0 thousand | Q3 2023: $571.0 thousand | Q1 2024: $960.0 thousand | Q2 2024: $975.0 thousand | Q3 2024: $1.21 million | Q1 2025: $1.78 million | Q2 2025: $2.04 million | Q3 2025: $2.79 million.
- Over the full 4 years of available data (2022 to 2025), FibroBiologics, Inc.'s Research And Development Expense has grown by 545.8%.
- Historical annual values: Fiscal year 2025: $7.41 million | Fiscal year 2024: $4.50 million | Fiscal year 2023: $2.37 million | Fiscal year 2022: $1.15 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: